Ad Hoc Group Statement on President’s FY 2022 Discretionary Funding Request

April 9, 2021 – The Ad Hoc Group for Medical Research issued the following statement in response to the proposed funding for the National Institutes of Health (NIH) in the President’s fiscal year (FY) 2022 budget request released today, including the establishment of a new Advanced Research Projects Agency for Health (ARPA-H):

The Ad Hoc Group for Medical Research enthusiastically applauds President Biden for proposing $51 billion in funding for medical research supported by the NIH as part of his FY 2022 proposal. We are eager to learn more about the proposal once the White House submits its detailed Budget next month, and we are immensely grateful for the President’s enthusiasm for biomedical research investments and his recognition of the value of an audacious investment in NIH to improve health for people in the U.S. and around the globe.

We also look forward to learning more about the proposed ARPA-H initiative to accelerate the implementation of research findings. Our community of patients, scientists, clinicians, academic and research institutions, and industry appreciates the President’s bold vision to promote transformational innovations against the full range of maladies that patients face, including cancer, diabetes, and Alzheimer’s, and we are committed to advancing science and discovery to make that dream a reality.

As we’ve seen with the mRNA vaccine platform that followed from NIH-supported research and is now helping us defeat COVID-19 – and as we know from all the groundbreaking medical and health interventions that came before it and will come after it – key to that goal will be ongoing robust funding growth in fundamental research supported by the NIH. The Ad Hoc Group stands ready to work with the White House and Congress to realize that vision. In FY 2022, we strongly support $51 billion for NIH, including no less than $46.1 billion for NIH’s base program level budget, as recommended by nearly 400 organizations and institutions.

In addition, the coronavirus pandemic continues to impact the nation as a whole, and medical research progress in all disease areas, with a disproportionate impact on women, minorities, and early career investigators in the research workforce. We continue to urge support for emergency resources, as outlined in the RISE Act, that will allow the NIH to “build back” the nation’s strong and diverse research workforce infrastructure and to continue to invest in broad and new research areas that will provide better health for patients in the future.

*****

The Ad Hoc Group for Medical Research is a coalition of nearly 400 patient and voluntary health groups, medical and scientific societies, academic and research organizations, and industry. The Ad Hoc Group has one mission: to enhance the federal investment in biomedical, behavioral, social, and population-based research by increasing the funding for the National Institutes of Health.